

## Nanoveu Ltd.

# **Collaborating with NYSE-listed Arrow Electronics**

Nanoveu (ASX:NVU) has just announced a collaboration between its semiconductor unit EMASS and Arrow Electronics (NYSE: ARW) to accelerate the adoption of its ECS-DoT chip, an Edge-AI focused chip that is highly energy efficient and performs tasks with incredible computational efficiency. The chip can handle 13 million AI parameters at once and process them at a rate translating to over 10 trillion AI operations per second per watt. It was lucrative enough before this latest deal, but NVU is now in an even better position, in our view.

## The significance of Arrow deal cannot be overstated

Arrow Electronics is a Colorado-headquartered provider of electronic components, such as chips, interconnects and sensors among others, to electronics manufacturers. The company is listed on the NYSE, is part of the Fortune-500 index and is capitalised at >US\$6bn. It generated revenues of nearly US\$28bn in 2024.

EMASS and Arrow Electronics will accelerate the deployment of ultra-low-power edge-AI solutions based on EMASS' ECS-DOT IP, combining Arrow's global reach, manufacturing reach and supply chain with EMASS' technology.

This deal will mean ECS-DoT will now have an easier path to potential customers, through heightened exposure (i.e. to Arrow's customer base) as well as having Arrow's manufacturing and supply chain capabilities. The companies will also work on enhanced SDKs, developer tools and reference designs to simplify evaluation and integration of ECS-DoT. The companies will showcase a joint reference design at SWITCH week in Singapore.

In our view, this is a game-changing deal for Nanoveu as it will provide very substantial opportunities for accelerated roll-out of its technology.

## Commercialisation early in 2026

Nanoveu previously stated it expects to receive initial volume purchase orders by the end of Q1 2026. Once commercialised, there are countless use cases, including drones and wearables. The entire Edge AI market is expected to grow at 33.3% CAGR for the rest of this decade to US\$270bn by 2030, all because of the shift to on-device processing.

## Valuation \$0.19 per share with more upside potential

We reiterate our previous valuation of Nanoveu at \$0.19 per share based on a peer-weighted approach. Please see <u>our previous notes</u> for further details on our valuation and the key risks to our thesis.


Share Price: A\$0.09

ASX:NVU
Sector: Technology
29 October 2025

Market cap. (A\$ m)	88.3
# shares outstanding (m)	981.1
# shares fully diluted (m)	1,397.9
Market cap ful. dil. (A\$ m)	125.8
Free float	100%
52-week high/low (A\$)	0.11/0.018
Avg. 12M daily volume ('1000)	6,514
Website	https://nanoveu.com

Source: Company, Pitt Street Research

## Share price (A\$) and avg. daily volume (k, r.h.s.)



Source: Refinitiv Eikon, Pitt Street Research

Valuation metrics	
Valuation (A\$ per share)	A\$0.19

Source: Pitt Street Research

Disclosure: Pitt Street Research directors own shares in Nanoveu.

**Analysts: Marc Kennis, Nick Sundich** 

Tel: +61 (0)4 3483 8134

marc. kenn is @pitts tree tresearch. com

nick.sundich@pittstreetresearch.com

## **General advice warning, Disclaimer & Disclosures**

### **Terms & Conditions**

The information contained herein ("Content") has been prepared and issued by Pitt Street Research Pty Ltd ACN 626365615 ("Pitt Street Research"), an Authorised Representative (no: 1265112) of BR Securities Australia Pty Ltd. ABN 92 168 734 530, AFSL 456663. All intellectual property relating to the Content vests with Pitt Street Research unless otherwise noted.

#### **Disclaimer**

Pitt Street Research provides this financial advice as an honest and reasonable opinion held at a point in time about an investment's risk profile and merit and the information is provided by the Pitt Street Research in good faith. The views of the adviser(s) do not necessarily reflect the views of the AFS Licensee. Pitt Street Research has no obligation to update the opinion unless Pitt Street Research is currently contracted to provide such an updated opinion. Pitt Street Research does not warrant the accuracy of any information it sources from others. All statements as to future matters are not guaranteed to be accurate and any statements as to past performance do not represent future performance.

Assessment of risk can be subjective. Portfolios of equity investments need to be well diversified and the risk appropriate for the investor. Equity investments in a listed or unlisted company yet to achieve a profit or with an equity value less than \$50 million should collectively be a small component of an individual investor's equity portfolio, with smaller individual investment sizes than otherwise. Investors are responsible for their own investment decisions, unless a contract stipulates otherwise.

Pitt Street Research does not stand behind the capital value or performance of any investment. Subject to any terms implied by law and which cannot be excluded, Pitt Street Research shall not be liable for any errors, omissions, defects or misrepresentations in the information (including by reasons of negligence, negligent misstatement or otherwise) or for any loss or damage (whether direct or indirect) suffered by persons who use or rely on the information. If any law prohibits the exclusion of such liability, Pitt Street Research limits its liability to the re-supply of the Information, provided that such limitation is permitted by law and is fair and reasonable.

## **General advice warning**

The Content is General Financial Advice but has been prepared for general information purposes only and is not (and cannot be construed or relied upon as) Personal Financial Advice nor as an offer to buy/sell/subscribe to any of the financial products mentioned herein. No investment objectives, financial circumstances or needs of any individual have been taken into consideration in the preparation of the Content.

Financial products are complex, entail risk of loss, may rise and fall, and are impacted by a range of market and economic factors, and you should always obtain professional advice to ensure trading or investing in such products is suitable for your circumstances, and ensure you obtain, read and understand any applicable offer document.

## **Disclosures**

Pitt Street Research has been commissioned to prepare the Content. From time to time, Pitt Street Research representatives or associates may hold interests, transact or hold directorships in, or perform paid services for, companies mentioned herein. Pitt Street Research and its associates, officers, directors and employees, may, from time to time hold securities in the companies referred to herein and may trade in those securities as principal, and in a manner which may be contrary to recommendations mentioned in this document.

Pitt Street Research receives fees from the company referred to in this document, for research services and other financial services or advice we may provide to that company. The analyst has received assistance from the company in preparing this document. The company has provided the analyst with communication with senior management and information on the company and industry. As part of due diligence, the analyst has independently and critically reviewed the assistance and information provided by the company to form the opinions expressed in the report. Diligent care has been taken by the analyst to maintain an honest and fair objectivity in writing this report and making the recommendation. Where Pitt Street Research has been commissioned to prepare Content and receives fees for its preparation, please note that NO part of the fee, compensation or employee remuneration paid will either directly or indirectly impact the Content provided.